clinical trial · NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Bristol-Myers Squibb·phase3·recruiting·n = 850
Non-small Cell Lung Cancer (NSCLC)PumitamigDurvalumab
brief summary
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
started
Mar 16, 2026
primary completion
Sep 18, 2030
completion
Dec 31, 2033
last updated
Apr 6, 2026
official title
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol